Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Osimertinib molecular profiling study in first-line EGFR-mutated advanced NSCLC
2017-002359-27Phase 2Active
- Sponsor
- AstraZeneca
- Start
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of osimertinib in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Primary endpoint: Proportion of patients with genetic and proteomic markers at disease progression. Started Oct 2017; status: active.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2017-002359-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002359-27.